TS-2021
Phase 1Biologic
TS-2021 is one of 33 biologic programs targeting Malignant Glioma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Afinitor
NovartisApproved
Norvir
AbbVieApproved
Lynparza
AstraZenecaApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Plaquenil
Jazz PharmaceuticalsApproved
Tafinlar
NovartisApproved
Ziagen
GSKApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tylenol
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TS-2021. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing Neurosurgical Institute